Biocon is one of the largest Biopharmaceutical company in India.Till recently company was mainly concentrating in statins which is a cholesterol lowering drug .But now company is seeking various growth opportunities in other segments and paying much attention for developing other biotechnology based branded formulations and contract research activities through its subsidiary Syngene and Clinical research through Clyngene.Branded formulation business is expected to grow about 30% in the coming year.Recently company launched 'INSUPEN' which is a reusable insulin pen.Company's agreement with foreign pharma companies for supply of products are also a positive step.Biocon's overseas operation in the countries like Malaysia ,Germany..etc are also moving in the right direction.Oral insulin is another important step which is going through clinical trials.Biocon's last quarter performance is a tad below expectations but the sharp cut in its share price makes it an attractive buy for long term investors .CMP is Rs.261/-
Disclaimer: This Blog,its owner,creator & contributor is neither a Research Analyst nor an Investment Advisor and expressing opinion only as an Investor in Indian equities. He/She is not responsible for any loss arising out of any information, post or opinion appearing on this blog.Investors are advised to do own due diligence and/or consult financial consultant before acting on any such information. Author of this blog not providing any paid service and not sending bulk mails/SMS to anyone.
Showing posts with label Biocon. Show all posts
Showing posts with label Biocon. Show all posts
Saturday, December 17, 2011
BIOCON LTD - BUY
Biocon is one of the largest Biopharmaceutical company in India.Till recently company was mainly concentrating in statins which is a cholesterol lowering drug .But now company is seeking various growth opportunities in other segments and paying much attention for developing other biotechnology based branded formulations and contract research activities through its subsidiary Syngene and Clinical research through Clyngene.Branded formulation business is expected to grow about 30% in the coming year.Recently company launched 'INSUPEN' which is a reusable insulin pen.Company's agreement with foreign pharma companies for supply of products are also a positive step.Biocon's overseas operation in the countries like Malaysia ,Germany..etc are also moving in the right direction.Oral insulin is another important step which is going through clinical trials.Biocon's last quarter performance is a tad below expectations but the sharp cut in its share price makes it an attractive buy for long term investors .CMP is Rs.261/-
Labels:
Biocon
Monday, October 25, 2010
FUTURE LEADERS OF INDIAN STOCK MARKET ?
Niche plays are always catching attention of the investor fraternity and commanding premium over others in stock market in any country. Everybody is confident about Indian growth based on the hard working of middle class to attain better standard of living and their changing style of spending. Similarly everybody in stock market is aware that today’s small caps and mid caps are tomorrow’s leaders, if it is backed by efficient promoters and scalable business models. Below I am presenting eight such stocks which are expected to turn as future leaders in 5-10 year time frame .All these stocks are familiar to all of you and most of them are trading with sufficient volume and market capitalization. This is not a recommendation to BUY these stocks at current level , but keep this in mind and take the advantage of any market correction going forward to build a portfolio .Companies promoted only by Indians promoters(or changing management in favor of Indians) are included in this list.
(1) ONMOBILE GLOBAL
Experienced management ,undisputed leadership position , aggressive expansion through organic and in organic route in a sector with huge opportunity is inviting attention to this MVAS player.
CMP – Rs .368
P/E Based on FY 2010 - 40 X
-----------------------------------------------------------------------------------------------------------
Increasing awareness of public about their health , Good brand Name,Rapid expansion to tier II cities are positive for this company .
It was earlier recommended at Rs.162/-
CMP - Rs 223/-
P/E Based on FY 2010 - 50 X
---------------------------------------------------------------------------------------------------------
(3) BIOCON
No need of explanation for one of the India’s largest Bio-Pharma companies .Successful commercialization of its oral insulin program is expected to change its fortune which is now going through Phase III of clinical trials.
CMP - Rs.445
P/E Based on FY 2010 - 35 X
--------------------------------------------------------------------------------------------------------------
This integrated agri company is catching attention mainly due to the future potential of the industry in which it is operating , strong R & D , reputed brand name, aggressive expansion plans and health of its balance sheet.We have discussed about it many times here .For more details ,search the blog.
CMP Rs.335
P/E Based on FY 2010 - 16 X
------------------------------------------------------------------------------------------------------------
It was one of the most successful IPO in last FY .The only pure listed company from the food service industry is the darling of FII’s and other institutional investors mainly because of the vast opportunities available in a highly populated country like India , backed by experienced promoters . Company is aggressively expanding its operations to countries like Sri Lanka ,Bangladesh ..etc. It also trying to clinch similar business relations with some other big brands of the west as in the case of DOMINO’s.
CMP Rs 507/-
P/E Based on FY 2010 - 92 X
-----------------------------------------------------------------------------------------------------------


6) CAIRN INDIA


India’s largest Non PSU oil producer is a hot subject among investors after the proposed takeover of Vedanta Group led by Anil Agarwal. The revival in world economies are expected to cause for a rise in oil prices and such an event will immensely benefit Cairn India.
CMP Rs.335/-
P/E Based on FY 2010 - 60 X
--------------------------------------------------------------------------------------------------------------
A steady performer led by an able banker. The low density of banks in India is offering lot of chances for expansion of branch network. This new generation technology driven bank will be one of the big beneficiary
CMP Rs 370/-
P/E Based on FY 2010 - 24 X
-----------------------------------------------------------------------------------------------------------
8) FORTIS HEALTHCARE
Even if its previous attempt to become a global player by taking over Parkway Holdings failed ,this health care provider is expected to grow exponentially under the leadership of young brothers in a sector with huge opportunity.
CMP Rs 163/-
P/E Based on FY 2010 - 143 X--------------------------------------------------------------------------------------------------------
Note :
If we follow the conventional methods of stock selection based on various valuation parameters ,none of the above may qualify for a BUY at present. But considering the opportunities available in these sectors where the mentioned companies are operating and the ability of managements behind these companies may make wonders going forward . So keep an eye on these companies and try to catch them in any decent correction and keep for long term for wealth creation.
Labels:
Biocon
,
Cairn India
,
jubilant food woeks
,
KAVERI SEED
,
onmobile
,
talwakar
,
yes bank
Subscribe to:
Posts
(
Atom
)















